161 related articles for article (PubMed ID: 26084224)
1. The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist.
Munoz M; Recio S; Rosso M; Redondo M; Covenas R
J Physiol Pharmacol; 2015 Jun; 66(3):421-6. PubMed ID: 26084224
[TBL] [Abstract][Full Text] [Related]
2. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
[TBL] [Abstract][Full Text] [Related]
3. The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile.
Muñoz M; Rosso M; González A; Saenz J; Coveñas R
Peptides; 2010 Sep; 31(9):1643-8. PubMed ID: 20542069
[TBL] [Abstract][Full Text] [Related]
4. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of peptide and pseudopeptide amides inhibiting the proliferation of small cell and epithelial types of lung carcinoma cells.
Nyéki O; Rill A; Schon I; Orosz A; Schrett J; Bartha L; Nagy J
J Pept Sci; 1998 Dec; 4(8):486-95. PubMed ID: 9927255
[TBL] [Abstract][Full Text] [Related]
6. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
7. The NK-1 receptor: a new target in cancer therapy.
Muñoz M; Rosso M; Coveñas R
Curr Drug Targets; 2011 Jun; 12(6):909-21. PubMed ID: 21226668
[TBL] [Abstract][Full Text] [Related]
8. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
Munoz M; Covenas R; Esteban F; Redondo M
J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
[TBL] [Abstract][Full Text] [Related]
9. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines.
Rosso M; Robles-Frías MJ; Coveñas R; Salinas-Martín MV; Muñoz M
Tumour Biol; 2008; 29(4):245-54. PubMed ID: 18781096
[TBL] [Abstract][Full Text] [Related]
10. Cancer progression and substance P.
Coveñas R; Muñoz M
Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
[TBL] [Abstract][Full Text] [Related]
11. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines.
Muñoz M; Rosso M; Coveñas R
Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801
[TBL] [Abstract][Full Text] [Related]
12. Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor.
González-Ortega A; Sánchez-Vaderrábanos E; Ramiro-Fuentes S; Salinas-Martín MV; Carranza A; Coveñas R; Muñoz M
Peptides; 2014 May; 55():1-12. PubMed ID: 24548567
[TBL] [Abstract][Full Text] [Related]
13. Effects of neuropeptide analogues on calcium flux and proliferation in lung cancer cell lines.
Bunn PA; Chan D; Stewart J; Gera L; Tolley R; Jewett P; Tagawa M; Alford C; Mochzuki T; Yanaihara N
Cancer Res; 1994 Jul; 54(13):3602-10. PubMed ID: 7516822
[TBL] [Abstract][Full Text] [Related]
14. Neurokinin-1 receptor: a new promising target in the treatment of cancer.
Muñoz M; Coveñas R
Discov Med; 2010 Oct; 10(53):305-13. PubMed ID: 21034671
[TBL] [Abstract][Full Text] [Related]
15. Esmolol activates endogenous neurokinin activity inhibiting infarction-induced arrhythmias in rats: novel mechanisms of anti-arrhythmia.
Wang LL; Han Y; Guo Z; Han SQ; Liu T
Regul Pept; 2013 Sep; 186():116-22. PubMed ID: 23994276
[TBL] [Abstract][Full Text] [Related]
16. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2.
Muñoz M; Rosso M; Aguilar FJ; González-Moles MA; Redondo M; Esteban F
Invest New Drugs; 2008 Apr; 26(2):111-8. PubMed ID: 17906845
[TBL] [Abstract][Full Text] [Related]
17. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
Muñoz M; Martinez-Armesto J; Coveñas R
Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287
[TBL] [Abstract][Full Text] [Related]
18. Involvement of substance P and the NK-1 receptor in cancer progression.
Muñoz M; Coveñas R
Peptides; 2013 Oct; 48():1-9. PubMed ID: 23933301
[TBL] [Abstract][Full Text] [Related]
19. [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P induces apoptosis in lung cancer cell lines in vitro.
Reeve JG; Bleehen NM
Biochem Biophys Res Commun; 1994 Mar; 199(3):1313-9. PubMed ID: 7511895
[TBL] [Abstract][Full Text] [Related]
20. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
